Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fastjel is a topical gel formulation containing 2.5% ketoprofen, a non-steroidal anti-inflammatory drug (NSAID) of the propionic acid class. Developed and extensively studied by Akdeniz University, particularly in the context of emergency medicine, Fastjel is utilized for the localized treatment of mechanical low back pain. Its mechanism of action involves the non-selective inhibition of cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes, which subsequently reduces the biosynthesis of prostaglandins responsible for pain and inflammation. By delivering the active ingredient topically, Fastjel aims to provide effective analgesia at the site of injury while minimizing the systemic exposure and associated adverse effects typically seen with oral or parenteral NSAIDs and opioids.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Fastjel.